{"artifact":{"id":"experiment_proposal-16db8026-4aae-496b-bea0-70c2596410e0","artifact_type":"experiment_proposal","entity_ids":"[]","title":"Experiment Proposal (Crux): Does manipulating orexin-A directly rescue cognitive deficits and circadian dysfunction in Alzheimer [ask-aa724961]","quality_score":0.6,"created_by":"Synthesizer","provenance_chain":"[]","content_hash":"93b27d6b44df0dc0a0bc68b90f3826769da9e76c0f10b95e82db596a84940339","metadata":{"aims":["Determine whether orexin-A rescue of cognitive deficits in AD models is a direct disease-modifying effect or secondary to arousal/wakefulness enhancement","Distinguish orexin receptor-mediated signaling effects from global wakefulness promotion using dual orexin receptor antagonism (DORA) as an arousal-matched control","Establish whether orexin-A modifies amyloid burden, tau phosphorylation, synaptic plasticity markers, and glymphatic function independently of behavioral state"],"source":"debate_crux","question":"Does manipulating orexin-A directly rescue cognitive deficits and circadian dysfunction in Alzheimer's disease models?","hypotheses":["If orexin-A produces disease-modifying effects, then orexin-A treated AD mice will show reduced amyloid/tau pathology and improved synaptic markers compared to DORA-treated mice with equivalent wake time","If orexin-A rescue is arousal-dependent, then DORA-treated mice with sleep consolidation matched to orexin-A wake periods will exhibit equivalent cognitive and pathological improvement","Time-of-day specific orexin-A dosing during the light phase (mouse sleep period) will reveal whether circadian-amplitude enhancement drives disease-modifying effects independent of total wake time"],"dissent_text":"The skeptic noted that orexin-A may worsen rather than rescue cognition in some AD models by increasing wakefulness and amyloid burden.; The expert cautioned that sedating interventions must be separated from disease-modifying effects.","est_cost_usd":78500.0,"persona_used":"Synthesizer","consensus_text":"Orexin biology should be tested with time-of-day dosing and sleep/circadian endpoints, not only cognitive behavior.; Dual orexin receptor antagonism may help amyloid clearance through sleep consolidation but could impair daytime cognition if mistimed.; Causal tests need amyloid/tau, synaptic plasticity, glymphatic, and locomotor rhythm readouts in the same experiment. |","skill_evidence":"","_schema_version":1,"datasets_queried":["dataset-d8372bd7-eded-4ef1-adde-e0058b42cc4c","dataset-allen_brain-SEA-AD-MTG-10x","dataset-192467e0-fe96-43cb-a64f-e891cdcff111","tabular_dataset-seaad-microglia-de","dataset-clinicaltrials.gov-ad_trial_tracker","tabular_dataset-d9439233-b413-4273-a003-b14bceb146d7","dataset-geo-GSE123456","tabular_dataset-b3889491-fc25-440e-863d-bc96f9d33c51","dataset-zenodo-10-5281-zenodo-1234567","dataset-allen_brain-SEA-AD"],"protocol_summary":"APP/PS1 or 5xFAD mice (12 months old, n=20/group) will receive 4-week chronic treatment via osmotic minipump: (1) Orexin-A (3nmol/day, ICV infusion during zeitgeber time 2-6, coinciding with mouse sleep phase), (2) DORA-22 (suvorexant, 10mg/kg IP at ZT2, produces equivalent wake consolidation without orexin receptor agonism), (3) Vehicle control, (4) Orexin-A + DORA-22 co-treatment (to test whether DORA blocks orexin-A disease-modifying effects), (5) Chemogenetic inhibition of orexin neurons (orexin-tDTomato-Cre with inhibitory DREADD) while administering peripheral orexin-A to isolate central vs. peripheral orexin signaling. Endpoint assessments performed at ZT4 on treatment day 28: (a) Cognitive: Morris water maze acquisition and reversal, Y-maze spontaneous alternation; (b) Circadian: home-cage locomotor activity monitoring throughout treatment, sleep-wake architecture via EEG/EMG telemetry; (c) Amyloid: ELISA for soluble/plaque Aβ40/42 in prefrontal cortex and hippocampus, Thioflavin-S plaque density; (d) Tau: AT8 and AT180 immunohistochemistry, Sarkowsky solubility assay; (e) Synaptic plasticity: Western blot for PSD95, synaptophysin, GluA1 phosphorylation, and CA1 LTP recording in acute slices; (f) Glymphatic function: in vivo CSF tracer (Texas Red-dextran) clearance assay via cisterna magna injection with real-time imaging of parenchymal distribution; (g) Molecular: RNA-seq of lateral hypothalamus and hippocampus for orexin receptor (HCRTR1/2) expression, downstream CREB/ERK signaling, and glymphatic-relevant genes (AQP4, GFAP). Pre-existing SEA-AD snRNA-seq data will be queried to map HCRTR1/2 expression across neuronal and glial cell types in human AD vs. age-matched controls, providing translational context.","debate_session_id":"sess_SDA-2026-04-26-gap-pubmed-20260410-184240-f72e77ae_task-aa724961","skill_invocations":[],"est_duration_weeks":16.0,"dataset_dependencies":["Allen Brain SEA-AD MTG 10x snRNA-seq","SEA-AD Differential Expression: AD vs Control (MTG)","TREM2 Expression by Cell Type","SEA-AD Microglia Differential Expression (AD vs. Controls)"],"falsification_criteria":"The disease-modification hypothesis will be falsified if: (1) DORA-treated mice show equivalent cognitive rescue and equivalent reduction in amyloid/tau burden as orexin-A treated mice; (2) Orexin-A treatment fails to alter amyloid burden, tau phosphorylation, or synaptic plasticity markers when wake time is matched by DORA co-treatment; (3) Orexin-A effects on pathology are completely abolished by DORA co-administration, indicating all effects are secondary to wakefulness rather than direct receptor signaling; (4) Central vs. peripheral orexin-A administration shows no differential effect on disease markers, suggesting any benefit is systemic/metabolic rather than neurobiological. The arousal hypothesis will be falsified if: (1) Orexin-A produces superior cognitive rescue and greater amyloid/tau reduction compared to DORA with equivalent wake consolidation; (2) Orexin-A enhances glymphatic tracer clearance and synaptic plasticity independent of total wake time; (3) DORA co-treatment blocks orexin-A-mediated disease-modifying effects on pathology.","predicted_observations":"If the hypothesis that orexin-A provides disease-modifying effects is correct: Orexin-A treated mice will show significantly greater reductions in hippocampal Aβ42 levels and Thioflavin-S plaque burden compared to DORA-treated mice, despite matched wake consolidation. Synaptic markers (PSD95, p-GluA1) will be elevated and LTP magnitude will be enhanced in orexin-A vs. DORA groups. Glymphatic tracer clearance rate will be accelerated in orexin-A mice. Critically, DORA co-treatment will block orexin-A-mediated reductions in amyloid/tau and cognitive improvement, demonstrating receptor-dependence. If the arousal-only hypothesis is correct: DORA and orexin-A groups will show equivalent cognitive improvement and equivalent reduction in amyloid burden, with no differential effect on synaptic plasticity or glymphatic function."},"created_at":"2026-04-27T03:20:42.645637-07:00","updated_at":"2026-04-27T03:20:42.645637-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"e68c2cc0-bf81-4344-b7b6-756747ccca57","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"Synthesizer"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"experiment_proposal-16db8026-4aae-496b-bea0-70c2596410e0","is_canonical":true,"supersede_chain":["experiment_proposal-16db8026-4aae-496b-bea0-70c2596410e0"]}